Our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Novartis is one of the world’s leading healthcare companies, and a major player in each of the sectors in which it operates. Its products are available in more than 140 countries around the world, and it employs around 100,000 people.
The Group’s activities are carried out by the Innovative Medicines (consisting of the Novartis Pharmaceuticals and Novartis Oncology business units) and Sandoz (generics and biosimilars) divisions. In 2022, global sales stood at $51.6 billion. Novartis’ strategy is based on an offer capable of responding to multiple therapeutic needs and constantly enriched with innovative solutions. In 2022, 743 million patients worldwide used a Novartis drug. The Group allocates substantial investments to innovation, which in 2022 reached 9.1 billion dollars, equal to 18% of turnover. Thanks to these resources, Novartis R&D is one of the strongest in the industry, with more than 150 products in the pipeline.
Novartis in Italy
Novartis is one of the largest pharmaceutical groups operating in Italy, its activities are spread throughout the country and, for more than twenty years, it has been a major player in innovation in the health area. With its activities, increasingly focused on the innovative drugs business, it plays a leading role in all the main therapeutic areas: cardiovascular, immunology, neuroscience, solid tumors, hematology. It is also a pioneer in the development of innovative therapeutic platforms, such as radioligands, siRNA and advanced therapies. Its headquarters are in Milan and the pharmaceutical production is concentrated in Torre Annunziata (Naples), one of the most important production hubs worldwide and one of the largest pharmaceutical sites in Southern Italy. Also part of the Novartis world is Advanced Accelerator Applications, specialized in radiopharmaceuticals based in Ivrea, Piemonte. In 2022, Novartis achieved sales of €1,722 million in Italy, of which almost €78 million was achieved through exports. Investments amounted to almost 70 million euros.